
When IV Therapy Goes Wrong: A Murder Charge, a Wrongful-Death Suit, and the Med-Spa Rules Now in Play
If you run an IV therapy or drip-bar business, or you're thinking about adding one, you've probably seen the headlines from October 2026 and wondered whether the risk has quietly changed. A Bronx operator was indicted for murder after a 27-year-old woman died following an NAD+ injection. A Lafayette, Indiana family sued after a 34-year-old woman died within about an hour of an IV drip. And Indiana has a new med-spa registration law that phases in through January 2027.
Most coverage lumps all of this into a single "crackdown on IV therapy." That framing misses what actually happened, and it leads clinicians to the wrong fixes. The two deaths are distinct events with distinct legal consequences — one criminal, one civil — and the law and the industry guidance are separate threads, not a response to either death. This guide separates those layers. It is the companion to our 2026 state-board enforcement guide, which covers the rule changes themselves; here we cover what happens when something goes badly wrong.

Quick answer
Two recent IV-therapy deaths — one from an NAD+ injection in the Bronx, one from a hydration drip in Lafayette, Indiana — both involved air embolism, according to the medical examiner and the coroner. The first produced a murder indictment against an allegedly unlicensed operator; the second produced a wrongful-death lawsuit against a med spa. Separately, Indiana's SB 282 creates a med-spa registration framework, and QUAD A and MedSpa Board issued joint IV-infusion safety guidance. Their shared message: IV therapy is a medical service that needs real clinical oversight.
The criminal ceiling: a murder indictment over an NAD+ injection
The sharpest end of the risk is a case out of the Bronx. On October 6, 2026, Luis Rojas Cabrera, 56, of Passaic, New Jersey, was arraigned on charges of second-degree murder, second-degree manslaughter, criminally negligent homicide, first-degree reckless endangerment, and unauthorized practice of a profession, according to the Bronx District Attorney's office.
The allegation, per the DA's release: on July 19, 2026, Rojas Cabrera administered a NAD+ intravenous injection to a 27-year-old woman at a business he operated in the Bronx — despite not being licensed to practice medicine in New York State. She became unconscious, was transported to a hospital, and was pronounced dead about an hour later.
The New York City Office of Chief Medical Examiner determined the cause of death to be cardiac air embolism "due to the introduction of air into the intravenous catheter inserted into the victim," the DA's office said. Bronx District Attorney Darcel D. Clark put it plainly: "This defendant was allegedly operating a medical clinic even though he was not licensed to practice medicine in New York State. A young woman seeking health benefits instead had her life cut tragically short."
Two details matter for anyone running a cash-pay clinic. First, CBS News New York reported that Rojas Cabrera referred to himself as a doctor but was licensed in the United States only as an esthetician — a reminder that "wellness center" branding does not confer prescriptive or administration authority. Second, the DA's office said investigators located two additional individuals who received injections from him.
Bail was set at $2 million cash, with $7 million bond and $7 million partially secured bond alternatives, and he is due back in court October 27, 2026. The DA's release carries the standard caution, worth repeating because it governs how you should read this: an indictment is an accusation, and a defendant is presumed innocent unless and until proven guilty. Defense attorney Donald Vogelman has said that if there was a homicide, it was an accident, and has called the murder count "outrageous," according to the New York Daily News and CBS News New York.
What this means for you: the charges in this case rest on the allegation that the operator was not licensed to practice medicine. The case does not draw a bright line for licensed clinicians, so take your own exposure questions to health-law counsel.
The civil ceiling: a wrongful-death suit over an IV drip
The second case shows that a serious claim does not depend on a criminal charge or on NAD+. In Lafayette, Indiana, the family of a 34-year-old woman filed a wrongful-death lawsuit after she died within roughly an hour of an IV drip hydration treatment.
According to reporting in the Journal & Courier and court records, she received the treatment at a Lafayette medical spa on March 2, 2026, around 3 p.m., drove herself to the emergency room, and was pronounced dead at 4:08 p.m. A coroner's autopsy performed March 6 found an air embolism — an air bubble in the right side of her heart — and noted that she had received IV therapy in the hour before her death. The autopsy report read, in part:
"The pericardium was opened and completely filled with water to entirely submerge the heart... Incisions were then made to the four chambers of the heart and an air bubble released from the right ventricle of the heart. There are no decomposition changes or other processes identified that would account for air being within the heart other than the recent intravenous therapy."
The lawsuit, filed by the woman's estate against the business and two named owners, alleges the defendants owed a duty to administer the IV drip in a reasonably careful manner and breached that duty by failing to use proper technique. It seeks wrongful-death damages and asks for a jury trial.
Note what is different here. No criminal charge has been reported in the Indiana case as of this writing, and the complaint as described alleges careless technique, not unlicensed practice. That is the civil ceiling: a lawsuit over how an infusion was administered.
Med-spa registration: Indiana SB 282
Separately from both cases, Indiana's governor signed Senate Bill 282, which creates a medical-spa registration framework, on March 5, 2026 (Public Law 136, per the Indiana General Assembly).
The law, codified at Indiana Code 25-22.5-12.5 according to Keffer Hirschauer LLP, phases in on a specific timetable. According to the Indiana General Assembly's digest and the American Med Spa Association (AmSpa), the law takes effect July 1, 2026; the medical board has until October 1, 2026, to build the registration process; and beginning January 1, 2027, registration is mandatory.
The core requirements, as described in the bill digest and AmSpa's summary:
Medical spas must register with the Medical Licensing Board, which must maintain a public database of registered facilities.
Each med spa must designate a "responsible practitioner" who meets defined qualifications and carries out specified oversight duties.
Med spas must notify the board after a serious adverse event.
The board may investigate a responsible practitioner over alleged violations.
Med spas are restricted from providing treatments outside the registered location, and must comply with existing advertising rules.
A law-firm analysis from Keffer Hirschauer LLP adds operational detail worth checking against the statute: it reads the law as requiring a 15-day adverse-event reporting window and carrying a fine of up to $5,000 for operating an unregistered facility. Because that reading comes from a firm's summary rather than the statute text itself, treat it as guidance to verify with your own counsel rather than as the final word.
AmSpa frames SB 282 as "the first of a series of nearly identical bills to pass," describing similar bills aimed at med spas and GLP-1 prescribing in Iowa, Florida, Arizona, and Colorado. That is the association's characterization, but it signals where registration-style rules may be headed next.
Watch for misinformation: Indiana's law is about registration and oversight — it is not a ban on IV therapy, and it is not specific to NAD+. The relevant question for you is whether your facility meets the statutory definition, which the law firm reads as covering any facility that provides medical treatments, uses prescription drugs (including IV, IM, or subcutaneous), and markets cosmetic, wellness, or longevity services.
The industry response: QUAD A and MedSpa Board's joint IV-safety guidance
On October 6, 2026, QUAD A (an accreditor) and MedSpa Board issued a joint statement on IV infusion safety, following recent FDA and CDC safety communications involving compounded injectable glutathione and related adverse events.
The statement's position is direct: "IV infusion therapy is a medical service." Among its recommendations:
"IV infusions should be prescribed by a physician, PA, or APRN acting within their scope of practice and applicable law."
"Appropriately licensed and credentialed staff should initiate the infusion and continuously monitor the patient for adverse events throughout the infusion."
Practices "should not administer IV therapies when the practice cannot verify the product's source or quality, when ingredients are not appropriate for the intended route of administration, or when the practice does not have the clinical capabilities to safely manage foreseeable complications."
Kate Dee, MD, Founder and CEO of MedSpa Board, framed it this way: "IV therapy should be treated like the medical service it is. That means appropriate clinical oversight, careful patient selection, ongoing monitoring, and confidence in both the source and quality of every product being administered."
MedSpa Board goes further in its own IV Infusion Standard, last reviewed September 2026. Among its requirements: documented monitoring check-ins "at minimum every 10–15 minutes," a patient never left unattended during an infusion, BLS-certified staff, and on-site emergency equipment including an AED, oxygen, and epinephrine. Notably, the standard lists NAD+ IV infusions on its prohibited-services list, writing that NAD+ carries "FDA-flagged contamination and endotoxin risk," is "not FDA-approved for IV use," and that "there is no medical reason to give NAD in IV form." That is MedSpa Board's position, stated in its own certification standard — it is not a statute, and it is not the FDA speaking — but it tells you how the accrediting bodies are drawing the line.

What this means for your practice: a compliance checklist
Across the two deaths, the new statute, and the joint guidance, the same requirements keep showing up. Audit against this list:
Confirm every person prescribing and administering is licensed in your state and acting within their scope — the starting point we walk through in IV certification for nurses.
Every infusion rests on a real prescriber-patient relationship and an individualized order — not a self-select menu.
Verify the source and quality of every product in the bag before you administer it.
Keep a patient continuously monitored, with documented check-ins at defined intervals (MedSpa Board's floor: every 10–15 minutes).
Stock and maintain on-site emergency equipment — AED, oxygen, epinephrine — and keep staff BLS-certified and trained on adverse-event response.
Check whether your state has a med-spa registration or responsible-practitioner law, and your registration deadline.
Confirm with your malpractice carrier that each specific therapy is a covered service, in writing.
Case or rule | Product / setting | Licensure issue raised | Air embolism identified | Current status |
|---|---|---|---|---|
Bronx | NAD+ injection, unlicensed clinic | Unlicensed to practice medicine (licensed only as esthetician) | Yes — cardiac air embolism, per OCME | Murder + related charges; presumed innocent |
Lafayette | IV drip hydration, med spa | Not addressed in the reporting reviewed | Yes — air in right ventricle, per coroner | Civil wrongful-death suit |
Indiana SB 282 | Registration framework | N/A — statutory | N/A | Phased: July 1 2026 effective; Jan 1 2027 registration required |
QUAD A / MedSpa Board | IV safety guidance | N/A — guidance | N/A | Joint statement Oct 6 2026 |

Frequently asked questions
Is NAD+ IV therapy FDA-approved? Not for IV use, according to the guidance issued by MedSpa Board, which states that NAD+ is "not FDA-approved for IV use" and lists NAD+ IV infusions among the services it will not certify. This is a standards body's position, not an FDA action, so confirm any specific product's status before you market it as approved.
Can I be criminally charged if something goes wrong in my IV clinic? The Bronx indictment involved an operator allegedly practicing without a medical license, and the defense calls the death an accident. Whether a licensed clinician faces criminal exposure after an adverse event depends on state law and the facts, so take that question to your health-law counsel.
What is a cardiac air embolism? Air entering the bloodstream through an intravenous line, which can travel to the heart and block blood flow. In the Bronx case, the medical examiner attributed death to air introduced through the IV catheter; in Lafayette, the coroner found an air bubble in the right ventricle of the heart.
Do I need to register my med spa? In Indiana, registration is required beginning January 1, 2027, according to AmSpa, if your facility meets the statutory definition. Check your own state, as registration and responsible-practitioner requirements vary.
What monitoring does IV therapy require? QUAD A and MedSpa Board advise continuous monitoring throughout the infusion, with MedSpa Board's standard specifying documented check-ins at least every 10–15 minutes and never leaving a patient unattended.
What emergency equipment should I have on hand? Per MedSpa Board's standard: an AED, oxygen, bag-valve-mask and airway equipment, blood-pressure cuff, pulse oximetry, and epinephrine, plus written response protocols for anaphylaxis, respiratory distress, and cardiac arrest.
The Bottom Line
The ceiling in this space is higher than a lot of clinics assume. One allegedly unlicensed operator faces a murder indictment; one med spa faces a wrongful-death suit; and Indiana has a med-spa registration law phasing in. The message from QUAD A and MedSpa Board is consistent: treat IV therapy as medicine — prescribed, sourced, monitored, and documented — not as a retail menu.
Ready to go from IV certified to IV service owner? The IV Therapy Course covers the compliance, scope-of-practice, and business setup you need to launch an IV line the right way. Or start with the free peptide training to see whether peptides belong in your service mix at all.
This article is for educational purposes for licensed healthcare professionals and is not legal advice. Scope of practice and IV therapy rules vary by state; confirm requirements with your licensing board and health-law counsel.
Sources
New Jersey Man Indicted for Murder in Fatal Injection Death — Bronx District Attorney, October 2026
Unlicensed Bronx wellness doctor arrested for murder for anti-aging shot that killed woman — New York Daily News, October 2026
Bronx man indicted on murder in NAD injection death — CBS News New York, October 2026
Woman dies after IV therapy at Lafayette medical spa — Journal & Courier, October 2026
Wrongful-death complaint, Lafayette, Indiana — Trellis (court record summary)
Senate Bill 282 — Compounding drugs; registration of medical spas — Indiana General Assembly, 2026
Indiana SB 282 Has Passed: What Med Spas Need to Know — American Med Spa Association, March 2026
Indiana Medical Spa Regulations — Keffer Hirschauer LLP
MedSpa Board and QUAD A Provide Joint Guidance on IV Infusion Safety — QUAD A, October 2026
IV Infusion Therapy Standard — MedSpa Board, September 2026